Has Asensus Surgical (ASXC) Reached The Bottom?
4:17 am Thursday, May 20th, 2021
In recent times, the medical device sector has come into a fair degree of focus among investors and one of the companies that could be tracked at this point in time is Asensus Surgical (NYSEAMERICAN:ASXC).
The Asensus Surgical stock had also been in considerable focus among investors this year and over the past three months, investors had a bit of a rollercoaster period. At one point, the Asensus stock experienced a strong rally that took the stock to new highs but after a point its corrected quite sharply as well. At this point, the stock can be picked up at a discount from its peak levels.
Asensus’ own projections for the future seem encouraging and on top of that, experts believe that the market might be ready for its flagship product Senhance System. One of the more important developments with regards to the company took place back in February this year, when the name was changed from TransEnterix to Asensus Surgical.
The rechristening of the company was part of a wider rebranding effort that was going to put more focus on the Senhance Surgical System, a digital laparoscopic platform that has been developed by Asensus. After this, the stock went on a strong rally that saw it hit its 52 weeks high of $6.95 a share back on February 10.
While Senhance remains the area of focus for Asensus at this point in time, it is also necessary to point out that the company is working on a wider range of products. The company is involved in making a range of machine learning powered medical devices that are specifically meant for different surgical processes.
That being said, it is currently an accepted fact that Senhance is the product that is expected to bring in the most money for Asensus. Experts believe that Senhance has the capability of emerging as a major disruptor in the field of laparoscopy.
